Search the Newsreel

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) reported a Q2 loss of $0.72 per share, outperforming the Zacks Consensus Estimate of a $0.98 loss. The company also exceeded revenue expectations, posting $41 million against a consensus estimate. Despite a mixed outlook for estimate revisions, RCUS shares have …

Arcus Biosciences earnings in focus as kidney cancer drug advances

Arcus Biosciences is reporting second-quarter earnings, with analysts expecting a narrower loss and increased revenue sequentially, though down year-over-year due to collaboration income. Investors are keen on updates regarding the company's lead kidney cancer candidate, casdatifan, and its clinical trials, as well as the …

Marcus & Millichap Brokers Sale of New Restaurant in Hixson, Tennessee Leased to Chick-fil-A

Marcus & Millichap's Taylor McMinn Retail Group has brokered the sale of a newly built Chick-fil-A restaurant in Hixson, Tennessee. The property, leased to Chick-fil-A on a 15-year ground lease with rent increases and extension options, was sold for approximately $2.8 million to a …

Marcus & Millichap earnings in focus as broker eyes profitability

Marcus & Millichap Inc. is set to announce its second-quarter earnings, with analysts expecting the company to return to profitability with 3 cents per share on $194 million in revenue. Investors will be focused on whether this improvement signifies durable operational trends amidst a …

Arcus Biosciences (RCUS) Earnings Date and Reports 2026

Marcus & Millichap (MMI) Q2 Earnings Report Preview: What To Look For

Marcus & Millichap Arranges Sale of Two-Property Multifamily Portfolio in South Jersey

Marcus & Millichap has successfully arranged the sale of a two-property, 36-unit multifamily portfolio in Vineland, New Jersey, for $5,525,000. The portfolio, which comprises townhome-style and bungalow-style buildings, attracted significant regional interest with 46 groups signing confidentiality agreements. This transaction highlights the growing appeal …

Marcus & Millichap Brokers $9.75M Sale and $7.3M Financing of 73-Unit Multifamily Property in Oakland California

Marcus & Millichap announced the sale of Garden Villas Apartments, a 73-unit multifamily property in Oakland, California, for $9.75 million, alongside arranging $7.3125 million in acquisition financing. The transaction highlighted the continued investor interest in affordable housing with long-term preservation opportunities and involved extensive …

Marcus & Millichap Brokers $8.3 Million Sale of Retail Property in Pembroke Pines, Florida

Marcus & Millichap has brokered the $8.3 million sale of West Pembroke Square, a 30,250-square-foot retail property in Pembroke Pines, Florida. The retail center, built in 1987, features 19 retail suites and was purchased by Jorge Gonzalez. Matt Albregts represented the seller, while Jonathan …

Florida’s 400-Unit Condo Sold to a Multifamily Rental Investor

Institutional Property Advisors (IPA), a division of Marcus & Millichap, brokered the $90.5 million sale of the 400-unit Ponte Verde at Palm Beach Lakes condominium in West Palm Beach, Florida, to New Jersey-based Kamson Corp. This transaction represents one of Florida's largest condominium-to-multifamily rental …

Marcus & Millichap’s Institutional Property Advisors Division Brokers $90.5 Million Sale of 400 Multifamily Units in West Palm Beach

Marcus & Millichap’s Institutional Property Advisors (IPA) division has brokered the $90.5 million sale of the 400-unit Ponte Verde at Palm Beach Lakes condominium in West Palm Beach, Florida, to Kamson Corp. This transaction represents one of Florida's largest condominium-to-multifamily rental conversions, driven by …

Circus SE Aktie: Countdown zur Hauptversammlung

Arcus Biosciences Inc expected to post a loss of 90 cents a share - Earnings Preview

Arcus Biosciences Inc is projected to report a loss of 90 cents per share in its upcoming earnings. This information is provided as an earnings preview from Refinitiv. The full article can be accessed through TradingView, which offers unlimited access to news sources.

Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?

Arcus Biosciences (RCUS) recently announced a clinical collaboration with Summit Therapeutics for a kidney cancer treatment, driving significant year-to-date and annual share price returns. Despite its recent momentum and a reported undervaluation against a fair value of $35.75, the stock's high P/S ratio of …

Marcus & Millichap Declares Regular Semi-Annual Dividend, Payable on October 6, 2026

Marcus & Millichap Inc. has announced a regular semi-annual dividend of $0.25 per share, totaling approximately $10.0 million. This dividend will be payable on October 6, 2026, to shareholders who are on record as of September 15, 2026. The company specializes in commercial real …

Marcus & Millichap Arranges $5.6M Sale of 34-Unit Multifamily Property in Sacramento California

Marcus & Millichap announced the $5.6 million sale of a 34-unit multifamily property, 915 Johnfer Way, in Sacramento, California. The transaction, facilitated by Adam Levin and Rob Johnston, included $3.7 million in acquisition financing secured by Marcus & Millichap Capital Corporation for the buyer. …

BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25

BofA Securities has raised its price target for Arcus Biosciences (NYSE: RCUS) to $29 from the previous target of $25. This adjustment reflects a more optimistic outlook on the company's valuation by the financial institution.

The Marcus Corp. renews upswing with 6% climb, sets new high (MCS:NYSE)

Shares of The Marcus Corporation rallied over 6% on Monday, pushing the stock above its 52-week high. This surge continues an upswing that began last week after the theater and hotel operator reported strong second-quarter earnings. The company's Q2 performance exceeded expectations, particularly in …

Press Release: Marcus & Millichap Declares Regular Semi-Annual Dividend of $0.25 Per Share

Marcus & Millichap, Inc. (MMI) announced that its Board of Directors has declared a regular semi-annual dividend of $0.25 per share. This dividend is payable on October 15, 2026, to common stockholders of record as of September 24, 2026. The declaration reinforces the company's …

Marcus & Millichap Brokers $13 Million Sale of Retail Center in Hacienda Heights, California

Marcus & Millichap has brokered the sale of Hacienda Village, a 23,645-square-foot retail center in Hacienda Heights, California, for $13 million. Built in 1963, the property features 17 retail suites leased to local food-and-beverage and service-oriented tenants. A Los Angeles-based private investor acquired the …

Marcus & Millichap Brokers $3.3M Sale of Retail Center in Metro Charlotte

Marcus & Millichap has brokered the $3.3 million sale of Village Shoppes, an unanchored retail strip center in Indian Trail, North Carolina, near Charlotte. The 12,075-square-foot property was fully leased at the time of sale to various tenants including Little Caesars and a dentist …

Spider-Man: Brand New Day Sets Marcus Theatres Opening-Day Record

Marcus Theatres announced record-breaking revenue and attendance figures, primarily driven by the opening weekend of "Spider-Man: Brand New Day." The film set new records for opening day box office and high opening weekend performance, supported by the continued success of "The Odyssey" and "Toy …

Marcus & Millichap Keeps Semi-Annual Dividend of $0.25 Per Share, Payable Oct. 6 to Holders of Record on Sept. 15

Marcus & Millichap (MMI) has declared a semi-annual dividend of $0.25 per share, which will be payable on October 6. Shareholders of record as of September 15 will be eligible to receive this dividend. The announcement was made on August 3, 2026.

Marcus & Millichap Sets Approximately $10M Dividend Payout

Marcus & Millichap Inc. (NYSE: MMI) has declared a regular semi-annual dividend of $0.25 per share, totaling approximately $10.0 million. The dividend will be payable on October 6, 2026, to shareholders of record as of September 15, 2026. Marcus & Millichap is a leading …

Marcus & Millichap brokers sale of mixed-use property in Morristown for $2.8M

Marcus & Millichap recently brokered the sale of a mixed-use property at 46 S. Park Place in Morristown for $2,847,604. The three-story building, renovated in 2025, includes three apartments and a retail unit. This transaction highlights the strong investor demand for well-located mixed-use assets …

Marcus Theatres Soars to Best Weekend of All Time

Marcus Theatres, a division of Marcus Corporation, announced its highest-grossing weekend in company history, driven by the record-breaking opening of "Spider-Man: Brand New Day," coupled with strong performances from "The Odyssey" and "Toy Story 5." The weekend set new records across multiple categories, including …

Marcus & Millichap Capital Corporation provides $4.798 million in acquisition financing for industrial property in Albert Lea

Marcus & Millichap Capital Corporation (MMCC) has secured $4.798 million in acquisition financing for an industrial property located at 1851 Margaretha Avenue in Albert Lea, Minnesota. The 127,869-square-foot property is currently leased to Green Bay Packaging. Michael Hughes of MMCC's Milwaukee office arranged a …

Arcus Biosciences, Inc. $RCUS Shares Acquired by Renaissance Technologies LLC

Marcus & Millichap, Inc. (NYSE:MMI) Plans $0.25 Dividend

3 Reasons Why Marcus (MCS) Is a Great Growth Stock

Price-Driven Insight from (RCUS) for Rule-Based Strategy

This article provides a price-driven analysis of Arcus Biosciences Inc. (RCUS) for rule-based trading strategies. It highlights weak near- and mid-term sentiment, potential resistance levels, and an exceptional short setup. The analysis offers specific institutional trading strategies, including position trading, momentum breakout, and risk …

How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo

Arcus Biosciences is expanding its ARC-20 platform with a new kidney cancer combination involving its HIF-2a inhibitor casdatifan and Summit Therapeutics' PD-1/VEGF bispecific antibody ivonescimab. This collaboration allows both companies to retain rights to their drugs while sharing costs, potentially broadening their kidney cancer …

Marcus (NYSE:MCS) Stock Rating Upgraded by Wall Street Zen

Marcus (MCS) Stock Pullback Follows Record Quarter And Valuation Questions

Marcus & Millichap Arranges Sale of Park Hill Apartments in Kerrville Texas

Marcus & Millichap has announced the sale of Park Hill, a 49-unit apartment property in Kerrville, Texas. The property, built in 1977, was marketed by Ben Kalter, Will Balthrope, and Drew Garza and was acquired by a Boerne-based buyer who plans to implement renovations …

Marcus & Millichap Arranges Sale of Multifamily Mixed-Use Property in Chicago

Marcus & Millichap announced the sale of a mixed-use property at 5655 West Fullerton Avenue in Chicago, featuring 24 multifamily units and four retail suites. The property, built in 1970, was sold to a private investor who sees significant value-add opportunities, including leasing vacant …